Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
Annovis Bio, Inc. (ANVS)
Company Research
Source: GlobeNewswire
BERWYN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other neurodegenerative diseases, was awarded a $1.7 million grant from the National Institutes of Health (NIH) for the Company’s long-term toxicology studies in rats and in dogs of its lead therapeutic compound ANVS401. Annovis began the animal toxicology studies in the fourth quarter of 2019 and expects to complete the studies in the third quarter of 2020. Annovis previously conducted one-month safety studies in mice, rats and dogs, and conducted two human safety studies in 120 healthy volunteers. In an interim analysis of an ongoing Phase 2a clinical trial in AD patients, the Data Safety Monitoring Board recommended the trial continue without modification. In these one-month studies, ANVS401 was shown to be well tolerated. Chronic toxicology studies are required to allow Annovis to test ANVS401 in hum
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace [Yahoo! Finance]Yahoo! Finance
- Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s MarketplaceGlobeNewswire
- /C O R R E C T I O N -- Today's Marketplace/PR Newswire
- Annovis to Host Year-End Investor Webcast on December 11, 2024 [Yahoo! Finance]Yahoo! Finance
- Annovis to Host Year-End Investor Webcast on December 11, 2024GlobeNewswire
ANVS
Earnings
- 11/11/24 - Beat
ANVS
Sec Filings
- 12/11/24 - Form 8-K
- 12/11/24 - Form 8-K
- 12/11/24 - Form 424B5
- ANVS's page on the SEC website